OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

Two-Step Immunotherapy Shows Promise Against Advanced Ovarian Cancer

In a small study presented at the annual meeting of the American Association of Cancer Research earlier this month, researchers from the University of Pennsylvania reported success with a new two-step immunotherapy approach to treating advanced ovarian cancer when combined with chemotherapy.

The process begins with treatment with a personalized vaccine, which is created from the patient’s own dendritic cells.  The vaccine is followed up with adoptive T-cell therapy, in which immune cells which have been removed from the patient, stimulated, and expanded in a lab, are re-injected into the patient.

In 65% of 31 patients, the initial vaccine alone led to either stable disease, or a partial response.  A subset of 11 patients who received the adoptive T-cell therapy had some clinical benefit.

Click here to read more about this study.